Hemispherx Adds Two New CFS Trial Sites Philadelphia (ots-PRNewswire) - Hemispherx Biopharma, Inc.(Amex:HEB) today announced that it completed contractual arrangementswithtwo new sites that will begin enrolling patients in aconfirmatoryPhase III clinical trial of the drug Ampligen(R) in the treatmentofChronic Fatigue Syndrome (CFS) that has been authorized by theFoodand Drug Administration. The company said that it has contracted with a total of 15sitesat major CFS treatment centers across the U.S. to participate inoneor more of the company's drug development programs for CFS. Thesitesare located in the states of New York, New Jersey, California,Illinois, Pennsylvania, North Carolina, Virginia, Florida, Utah,Nevada and Alabama. Eight of these sites are participating in thePhase III clinical trials, while the others are participating intheopen-label treatment protocol. Hemispherx said that patients who have been enrolled in thecurrent Phase III clinical trials and who have completed requiredbaseline evaluations at previously announced sites have beguntreatment. Under the protocol authorized by the Food and DrugAdministration, the confirmatory Phase III trial includes amulti-week baseline period in which patients are evaluatedquantitatively for physical and cognitive performance. After thisperiod, patients are selected at random to receive either aplaceboor Ampligen(R). The treatment is double-blinded, meaning thatneitherthe physicians nor the patients are aware of which patients arereceiving the placebo or the drug until after the trial iscompleted. To the company's knowledge, Hemispherx is the only companywithauthorized Phase III studies in the U.S. for CFS and the onlycompanywith a pending application for full marketing approval in theEuropean Union. The Center for Disease Control (CDC) estimatesthatCFS affects approximately 500,000 Americans and various medicalstudies suggest a similar number of Europeans are affected aswell. Hemispherx Biopharma, which is based in Philadelphia, is apharmaceutical company engaged in the manufacture and globalclinicaldevelopment of new drug entities in the nucleic acid (NA) classforchronic viral diseases and disorders of the immune systemincludingCFS, hepatitis B and hepatitis C. Information contained in this news release, other thanhistoricalinformation, should be considered forward-looking and is subjecttovarious risk factors and uncertainties. For instance, thestrategiesand operations of Hemispherx involve risks of competition,changingmarket conditions, changes in laws and regulations affectingtheseindustries and numerous other factors discussed in this releaseandin the Company's filings with the Securities and ExchangeCommission.Accordingly, actual results may differ materially from those inanyforward-looking statements.ots Original Text Service: Hemispherx Biopharma, Inc.Internet: http://www.newsaktuell.deContact:William A. Carter, M.D., CEO and Chairman of Hemispherx Biopharma(USA) 215-988-0080William J. Jenks, Media(USA) 212-232-2222, fax, (USA) 212-232-3232, orSharon Will, Investor Relations(USA) 212-572-0762, fax, (USA) 212-572-0764of Broadgate for HemispherxWeb site: http://www.hemispherx.come-mail:

NA_global@newsaktuell.de

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.